Drug Profile


Alternative Names: Allogeneic ex-vivo expanded placental adherent stromal cells; Allogeneic mesenchymal-like adherent stromal cells; PLacental eXpanded cells

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Pluristem Therapeutics
  • Developer Charite of Berlin; Pluristem Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Cell differentiation modulators; Cell replacements; Dendritic cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Preeclampsia; Thromboangiitis obliterans
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Intermittent claudication; Muscle injury
  • Phase I/II Peripheral arterial disorders
  • Phase I Pulmonary arterial hypertension
  • Preclinical Duchenne muscular dystrophy; Ischaemic heart disorders; Preeclampsia; Tendon injuries

Most Recent Events

  • 17 Jan 2017 The Paul Ehrlich Institute clears a phase III trial in Critical limb ischaemia
  • 12 Jan 2017 Pluristem announces intention to submit and marketing application for the approval of PLX PAD in Europe
  • 12 Jan 2017 Pluristem completes enrolment in its phase II trial for Intermittent claudication in USA, Germany, South Korea, Israel (NCT01679990)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top